bioAffinity Adds Leading Lung Cancer Experts to Advisory Board

bioAffinity Technologies, Inc. ( (BIAF) ) has issued an announcement.

On February 9, 2026, bioAffinity Technologies appointed three nationally recognized pulmonary and lung cancer specialists — David Ost of MD Anderson Cancer Center, Daniel Sterman of NYU Langone Health, and J. Scott Ferguson of the University of Wisconsin — to its Medical and Scientific Advisory Board. They join an existing panel of lung health and oncology experts who advise on clinical, scientific, and commercial strategy.

The board expansion is intended to support broader adoption and clinical integration of CyPath Lung, the company’s noninvasive diagnostic test designed to detect lung cancer early in high-risk patients with indeterminate pulmonary nodules. By deepening its access to leading clinicians in interventional pulmonology and thoracic oncology, bioAffinity is positioning CyPath Lung as a potential standard-of-care tool in lung cancer diagnosis, with implications for improved patient outcomes and greater market penetration in lung cancer diagnostics.

The most recent analyst rating on (BIAF) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

Spark’s Take on BIAF Stock

According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral.

The score is held down primarily by weak financial performance (declining revenue, large losses, very negative ROE, and negative operating cash flow). Technicals also lean bearish (below moving averages and negative MACD). Positive corporate updates (CAP accreditation and CyPath® Lung traction) and the lack of a meaningful P/E due to losses provide only limited offset.

To see Spark’s full report on BIAF stock, click here.

More about bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive diagnostics and early cancer detection, particularly for lung disease. Its first product, CyPath® Lung, is a sputum-based Laboratory Developed Test that uses flow cytometry and artificial intelligence to detect early-stage lung cancer with high reported sensitivity and specificity.

The test is marketed through its subsidiary Precision Pathology Laboratory Services and targets high-risk patients with small indeterminate pulmonary nodules. The company aims to integrate CyPath Lung into standard care pathways, addressing a significant need in lung cancer screening and diagnosis.

Average Trading Volume: 100,868

Technical Sentiment Signal: Sell

Current Market Cap: $3.83M

For an in-depth examination of BIAF stock, go to TipRanks’ Overview page.